Gonadorelin: Side Effects & Safety
Part of the Gonadorelin Complete Guide
Research Peptides
We may earn a commission if you purchase through this link, at no extra cost to you.
Overall Safety Profile
Gonadorelin is identical to endogenous GnRH, providing excellent biological compatibility. It is FDA-approved as a diagnostic agent (Factrel) with a well-established safety profile for acute use. Side effects with pulsatile subcutaneous use are minimal.
Reported Side Effects
- Injection site reactions: Mild and transient
- Headache: Occasionally reported
- Flushing: Transient
- Nausea: Rare
Important Limitations
Critical: Continuous (non-pulsatile) administration desensitizes GnRH receptors and paradoxically suppresses LH/FSH — the opposite of the intended effect. Proper dosing intervals (not continuous infusion) are essential. Long-term safety data for off-label HPG axis maintenance during TRT is limited.
Contraindications
- Hormone-dependent cancers (prostate, breast)
- Pregnancy (may affect pregnancy maintenance)
- Known hypersensitivity to GnRH or analogs